Remove Clinical Supply Remove DNA Remove Drug Development
article thumbnail

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Conversations in Drug Development Trends

For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition.

article thumbnail

Rapid delivery of toxicological material

Drug Target Review

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. In recent years, the biopharmaceutical industry has identified rapid Toxicology (Tox) material supply as the new critical path to IND readiness.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The golden era of GLP-1 drugs: How will it impact medicine and society?

BioPharma Drive: Drug Pricing

However, with this kind of promise comes more scientific, ethical and financial questions that healthcare providers and drug development professionals must seriously consider. As more people take them and their uses grow, so does their potential. Its new CEO has to figure out what’s next.

article thumbnail

FDA’s AI tool ‘Elsa’ is here, and the industry has questions

BioPharma Drive: Drug Pricing

These are exactly the applications where current generative AI … completely excels and where we see similar gains in drug development and scientific review internally at Lantern Pharma,” he said. Bloomberg 23andMe’s DNA Data Gets Boosted $305 Million Bid in New Auction View all Events 17 JUN Webinar | 10:30 a.m.

FDA 130
article thumbnail

Transforming cancer care through clinical excellence

Drug Target Review

I sequenced the complementary DNA (cDNA) encoding RAS GTPase Activating Protein, a protein known that regulates cell growth, differentiation and survival of cells; mutations in these proteins are linked to cancer. My proudest achievement is my leadership journey building legacy organisations, processes and tools in clinical operations.